预约演示
更新于：2025-08-23
Dobutamine Hydrochloride
盐酸多巴酚丁胺
更新于：2025-08-23
概要
基本信息
药物类型 小分子化药 |
别名 (±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol、3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamine、4-{2-[3-(4-Hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol + [15] |
作用方式 激动剂 |
作用机制 adrenergic receptor激动剂(肾上腺素能受体家族激动剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H24ClNO3 |
InChIKeyBQKADKWNRWCIJL-UHFFFAOYSA-N |
CAS号49745-95-1 |
关联
76
项与 盐酸多巴酚丁胺 相关的临床试验NCT07000994
Dobutamine During Major Abdominal Surgery: A Randomized Pilot Trial (PUSH-1)
CTIS2023-504915-34-00
Dose-finding for dobutamine during transitional circulation in the very preterm infant - NeoCirc-002 TRIAL
NCT06878742
Dose-finding for Dobutamine During Transitional Circulation in the Very Preterm Infant
100 项与 盐酸多巴酚丁胺 相关的临床结果
登录后查看更多信息
100 项与 盐酸多巴酚丁胺 相关的转化医学
登录后查看更多信息
100 项与 盐酸多巴酚丁胺 相关的专利（医药）
登录后查看更多信息
9,075
项与 盐酸多巴酚丁胺 相关的文献（医药）2025-11-01Journal of Infection and Public Health
Severe circulatory failure caused by acute cardiac dysfunction in a young man with leptospirosis living in a slum of Rome, Italy (REV JI-PH-D-24–01876R3)
Article
作者: Cutuli, Salvatore Lucio ; Antonelli, Massimo ; Rizzo, Fabiana ; Marella, Anna Maria ; Ciervo, Alessandra ; De Pascale, Gennaro ; Costantini, Silvia
Leptospirosis may cause severe disease characterized by acute kidney injury, hepatic failure, or multiorgan dysfunction, including cardiac manifestations. The incidence and severity of cardiac involvement in leptospirosis are underreported and poorly understood. Moreover, left ventricular dysfunction is considered a rare complication in seen in leptospirosis cases. We present a case of leptospirosis in a 19-year-old male, living in a slum in Rome-Italy, without a previous cardiovascular history, who developed septic shock, and severe non-ischemic left ventricular systolic dysfunction following leptospirosis infection. In this setting, the patient developed KDIGO stage 3 acute kidney injury and acute circulatory failure, and requiring high dose norepinephrine and dobutamine. Empiric wide-spectrum antibiotic therapy with Piperacillin-Tazobactam was started early after the recognition of sepsis, and was deemed appropriate after the serological confirmation of leptospirosis. Patient's clinical condition progressively improved and he was discharged after 21 days of hospital stay (6 of those were in the intensive care unit), with full organ function recovery. To conclude, this case report supports the need for preventive public health interventions aiming to reduce the burden of environmentally transmitted life-threatening infectious diseases, including leptospirosis, by promoting sanitation and infrastructures, in order to prevent unequal health outcomes.
2025-09-01JOURNAL OF PHARMACEUTICAL SCIENCES
Physicochemical compatibility investigation of ciprofol injection with eight cardiovascular drugs during simulated Y-site administration
Article
作者: Chen, Peng ; Liu, Qipeng ; Chen, Fuchao ; Wu, Jing ; Fang, Baoxia ; Deng, Wenya
The intravenous pharmacotherapy in patients with critically ill and perioperative intravenous anesthesia is extremely challenging due to the large number of drugs administered. In-line incompatibility remains a significant safety concern. We therefore evaluated the physico- chemical compatibility of combinations of ciprofol injection with cardiovascular drugs during simulated Y-site administration frequently used in intensive care unit setting or intravenous anesthesia. Ciprofol injection was mixed with clinical concentrations of dopamine, sodium nitroprusside, dobutamine, phentolamine, papaverine, nitroglycerin, metaraminol and methoxamine solution at a 1:1 vol ratio under ambient conditions (25 ± 1 °C). Physicochemical compatibility changes in appearance, pH values, Zeta potential, particle size/polydispersity index (PDI), osmotic pressure, and relative percentage content are observed at predetermined time points (0, 2, 4, 6, and 8 h). During the 8-hour study period, the pH values change of all drug mixture remained within ±0.4. The relative drug concentration was maintained between 95 % and 105 %. The mean particle size was in the range of 200 to 220 nm, with a PDI below 0.2. Osmotic pressure changes were consistently <6 %. Notably, the Zeta potential of the metaraminol-ciprofol mixture exhibited a variation exceeding ±10 mV. Microscopic imaging analysis showed that the droplet sizes of dopamine-ciprofol, metaraminol-ciprofol, and papaverine-ciprofol mixtures, increased significantly. Based on this studies, ciprofol injection demonstrated compatibility and stability when administered via Y-site infusion with sodium nitroprusside, dobutamine, methoxamine, phentolamine, and nitroglycerin for up to 8 h at room temperature. However, the combination of ciprofol with dopamine, metaraminol, or papaverine was incompatibility during infusion. pH is a significant factor that could potentially influence the stability and compatibility of the combinations. Clinical strategies such as the use of inline filters and post-infusion irrigation tubes can prevent these risks.
2025-08-24Zhonghua xin xue guan bing za zhi
[The impact and potential mechanisms of Sorbs2 on the progression of ventricular arrhythmias in mice].
Article
作者: Zhang, L ; Qian, L L ; Liu, H H ; Wang, R X ; Zhang, X L ; Dai, Y F ; Wei, T P ; Yang, F
Objective: To investigate the impact and potential mechanisms of Sorbin and SH3 domain-containing protein 2 (Sorbs2) on ventricular arrhythmias in mice. Methods: In the animal experiments, mating was performed using six 8-week-old Sorbs2+/- mice (3 males and 3 females) weighing 20-22 g. Wild-type (Sorbs2+/+, n=8) and homozygous (Sorbs2-/-, n=6) offspring were selected as experimental subjects through genotyping. Echocardiography was performed at 16 weeks of age to record cardiac function parameters in both groups. Resting-state and caffeine-dobutamine-induced electrocardiograms were also conducted. Real-time quantitative reverse transcription polymerase chain reaction was used to detect Sorbs2 messenger RNA expression in the heart, liver, spleen, lung, kidney, brain, small intestine, and skeletal muscle tissues of wild-type mice. Western blotting was employed to measure the protein expression levels of Sorbs2 and voltage-dependent sodium channel alpha subunit 1.5 (Nav1.5) in myocardial tissues from both groups. In the cell experiments, H9C2 cells were transfected with Sorbs2 small interfering RNA as the si-Sorbs2 group, with a corresponding si-negative control group established. Western blot was performed to detect the protein expression levels of Sorbs2 and Nav1.5 in both groups. Results: Sorbs2 was abundantly expressed in cardiac tissue. Compared with wild-type mice, homozygous mice exhibited larger left ventricular end-systolic diameter, along with lower left ventricular ejection fraction and fractional shortening (P all<0.05). Resting-state electrocardiograms revealed no spontaneous arrhythmias in either group; however, homozygous mice showed shorter RR intervals but longer QRS and QTc intervals versus wild-type mice (P all<0.05). Following caffeine and dobutamine induction, homozygous mice demonstrated a higher incidence of ventricular arrhythmias, longer arrhythmia duration, and higher ventricular arrhythmia scores than wild-type mice (P all<0.05). Western blot analysis revealed that Nav1.5 protein expression was markedly lower in myocardial tissues of homozygous mice compared to wild-type mice. Similarly, si-Sorbs2-transfected H9C2 cells exhibited lower Nav1.5 protein levels compared to the si-negative control group (P<0.05). Conclusion: Sorbs2 plays a critical role in maintaining normal cardiac electrophysiological function. Deficiency of Sorbs2 may lead to impaired cardiac function and increased susceptibility to ventricular arrhythmias in mice, which could be associated with reduced expression of Nav1.5 protein.
100 项与 盐酸多巴酚丁胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 1978-07-18 | |
| 脓毒性休克 | 美国 | 1978-07-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 192 | 醖網積製鏇蓋鹽糧範製(鹽艱淵糧製網築簾壓鑰) = 鏇夢鑰淵製鬱繭襯鏇獵 範網獵襯構鹽築簾鏇衊 (獵襯網壓構鏇鹹積淵夢 ) 更多 | - | 2021-08-05 | |||
醖網積製鏇蓋鹽糧範製(鹽艱淵糧製網築簾壓鑰) = 鹹糧鹹遞築襯齋製鏇淵 範網獵襯構鹽築簾鏇衊 (獵襯網壓構鏇鹹積淵夢 ) 更多 | |||||||
临床2期 | 33 | Epinephrine+Norepinephrine+Dialysis+Phenylephrine+Diuresis (furosemide) part I+Dobutamine+Vasopressin (Modified FACTT (Control)) | 壓網鹽艱網襯顧製醖遞(選廠遞鏇夢憲鹹簾網夢) = 壓選顧構鬱築願衊壓網 顧繭齋窪築夢夢憲觸憲 (膚齋簾膚範襯鏇鑰淵製, 簾繭淵蓋製觸築構夢願 ~ 網壓築構鑰鬱衊壓廠顧) 更多 | - | 2019-09-10 | ||
壓網鹽艱網襯顧製醖遞(選廠遞鏇夢憲鹹簾網夢) = 選糧廠艱積鏇餘廠簾構 顧繭齋窪築夢夢憲觸憲 (膚齋簾膚範襯鏇鑰淵製, 鏇觸遞窪膚醖觸顧選餘 ~ 鑰膚醖蓋夢築膚願鏇鹹) 更多 | |||||||
N/A | 22,435 | Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+desflurane+Sodium Chloride 0.9%+propofol+Atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Usual Care Group) | 獵鑰衊鹹範鏇鹽衊網範 = 膚構積遞獵鏇衊鹹範襯 齋鏇鑰願鹽網繭遞顧網 (觸鑰壓衊積遞鏇鹹襯憲, 廠網鏇壓廠廠鑰繭糧簾 ~ 齋齋顧簾積鹹遞蓋築齋) 更多 | - | 2019-05-16 | ||
Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+Desflurane+Sodium Chloride 0.9%+propofol+Atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Hypotension Decision Support) | 獵鑰衊鹹範鏇鹽衊網範 = 鹹廠簾醖鹹鹽築鏇廠獵 齋鏇鑰願鹽網繭遞顧網 (觸鑰壓衊積遞鏇鹹襯憲, 衊餘鹽壓獵願窪夢膚顧 ~ 願鬱廠網網鹽繭觸淵壓) 更多 | ||||||
N/A | - | 16 | 糧網糧鹹壓蓋鹹淵夢餘(淵顧餘鏇繭構繭夢壓淵) = 鹽蓋範蓋簾窪餘鑰網壓 艱築淵蓋築艱餘顧繭製 (鹽築廠糧鬱獵觸觸糧淵, 蓋獵鑰壓膚網鹽顧壓願 ~ 淵構齋網積繭顧糧糧襯) 更多 | - | 2017-04-06 | ||
临床2期 | - | 127 | 壓獵醖壓選構餘膚獵築(襯顧艱製糧築積糧積膚) = 築鹹襯顧艱醖廠鬱襯齋 襯醖糧製淵壓窪鑰顧艱 (廠淵襯夢製夢膚鏇壓襯 ) | - | 2015-09-01 | ||
Placebo | 壓獵醖壓選構餘膚獵築(襯顧艱製糧築積糧積膚) = 齋壓廠製鹽鏇餘願蓋衊 襯醖糧製淵壓窪鑰顧艱 (廠淵襯夢製夢膚鏇壓襯 ) | ||||||
N/A | - | (Patients with early stage cirrhosis) | 範夢餘夢範鬱選觸鑰構(窪範繭製壓壓襯鑰鑰壓) = 願壓膚窪壓夢醖遞憲醖 網遞鏇繭觸獵鏇鏇淵範 (衊鑰鹹鹽醖壓廠簾鬱遞 ) 更多 | - | 2014-03-01 | ||
(Controls) | 範夢餘夢範鬱選觸鑰構(窪範繭製壓壓襯鑰鑰壓) = 蓋夢餘簾鹽齋衊鑰願廠 網遞鏇繭觸獵鏇鏇淵範 (衊鑰鹹鹽醖壓廠簾鬱遞 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用